Powerhouse Ventures Limited (ASX:PVL)

Verve Therapeutics Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 7, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	14	5	6	8	9	2
Market Cap Growth	137.43%	-23.07%	-20.00%	-15.37%	394.97%	-7.02%
Enterprise Value	12	2	-5	3	6	0
Last Close Price	0.09	0.04	0.05	0.07	0.10	0.05
PE Ratio	4.88	11.92	8.75	-	-	-
PS Ratio	3.38	4.42	5.08	16.13	-39.23	2.79
PB Ratio	0.98	0.44	0.59	0.80	1.20	0.35
P/TBV Ratio	1.08	0.44	0.59	0.80	1.20	0.35
EV/Sales Ratio	2.89	1.64	-	6.28	-	0.22
EV/EBITDA Ratio	-	-	-	-	-	1.75
EV/EBIT Ratio	3.54	3.94	-	-	-	1.78
Debt / Equity Ratio	-	-	-	-	-	0.00
Debt / EBITDA Ratio	-	-	-	-	-	0.15
Asset Turnover	0.32	0.10	0.12	0.06	-	0.11
Quick Ratio	5.89	28.33	31.82	18.70	52.00	18.73
Current Ratio	5.99	28.98	32.36	18.93	52.49	19.27
Return on Equity (ROE)	19.78%	3.73%	7.00%	-3.30%	-22.30%	-0.83%
Return on Assets (ROA)	16.35%	2.59%	3.21%	-2.79%	-13.47%	0.80%
Return on Capital (ROIC)	17.10%	2.61%	3.26%	-2.84%	-13.63%	0.81%
Return on Capital Employed (ROCE)	22.50%	4.10%	5.00%	-	-	1.50%
Earnings Yield	17.48%	8.39%	11.43%	-3.65%	-15.80%	-2.35%
FCF Yield	-	-11.25%	-6.17%	-7.80%	-9.43%	-18.44%
Buyback Yield / Dilution	-21.78%	-	-16.76%	-51.04%	-114.35%	-9.37%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.